Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mapatumumab in Relapsed/Refractory Non-Hodgkin's Lymphoma
NCT00094848Phase 2Completed
- Sponsor
- Human Genome Sciences
- Start
- Jun 2004
- Primary completion
- Dec 2006
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of mapatumumab in non-Hodgkin lymphoma (NHL) (2 arms), sponsored by Human Genome Sciences. Primary endpoint: Tumor Response. Started Jun 2004; status: completed.
02
Drugs
mapatumumab
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00094848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00094848.